Objective: The relationship between hypogonadism and erectile dysfunction (ED) has not been completely clarified. Data derived from studies evaluating the effect of testosterone (T) replacement therapy (TRT) on patients with ED have yield mixed results. The purpose of the present study was to evaluate the efficacy and safety of a 50 mg/day of 1% hydroalcoholic testosterone gel applied on non-scrotal skin for hypogonadal men with sexual dysfunction.
Material And Methods: We studied a consecutive series of 85 hypogonadal (total testosterone < 12 nmol/L) men (mean age 51.0 +/- 14.0 years) attending our Andrological Unit. Patients were interviewed using ANDROTEST structured interview, a 12-item tool previously validated for the screening of hypogonadism in patients with sexual dysfunction. Patients were also invited to complete erectile function domain of International Index of Erectile Function (IIEF-6;11). Different clinical and biochemical parameters were evaluated at baseline and after 6 months of TRT.
Results: Subjects with ED at baseline (61.2%) showed significant increase of IIEF-6 score after 6 months of TRT (9.7 +/- 7.7 vs. 14.6 +/- 9.8, p < 0.001). Furthermore, subjects with more severe hypogonadism at baseline (T in the lowest quartile) showed the best increase in IIEF-6 score. All haematological and biochemical parameters tested remained in the normal rage at the end of the study.
Conclusions: Our study demonstrated that 1% hydroalcoholic testosterone gel is an effective and safe treatment option in subjects with ED.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development of a transdermal gel for reversible male contraception.
Contraception
January 2025
Division of Endocrinology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California; Clinical and Translational Science Institute, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California.
While there are several easy-to-use reversible female contraceptives, little is available for men. Introduction of novel, cost-effective male contraceptives could have important downstream global health and economic benefits. Currently, nearly half of all pregnancies globally are unintended, with many resulting in unsafe abortions, a significant burden for women and families in many countries.
View Article and Find Full Text PDFPatients deserve better information on new drugs.
BMJ
October 2024
Department of Health Policy, London School of Economics and Political Science, London, UK.
Effects of metformin and curcumin in women with polycystic ovary syndrome: A factorial clinical trial.
Phytomedicine
December 2024
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran; Department of Biostatistics and Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran. Electronic address:
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women, associated with dyslipidemia, insulin resistance, and hormonal imbalances. Metformin and curcumin have shown promise in improving these metabolic and hormonal parameters individually, but their combined effects in PCOS remain unclear.
Methods: We conducted a randomized, double-blind, placebo-controlled, 12-week factorial trial involving 200 women with PCOS.
Androgen Society Position Paper on Cardiovascular Risk With Testosterone Therapy.
Mayo Clin Proc
November 2024
Departments of Biochemistry and Urology, Boston University School of Medicine, Boston, MA.
Article Synopsis
- * The TRAVERSE study, published in June 2023, found no increased risk of major cardiovascular events in men receiving testosterone therapy compared to a placebo, countering earlier studies that suggested potential risks.
- * Based on the TRAVERSE findings and extensive previous research, the Androgen Society concludes that testosterone therapy is not linked to higher risks of heart attacks, strokes, or cardiovascular deaths.
Single-arm study of testosterone gel replacement therapy and ambulatory blood pressure outcomes in men with hypogonadism.
Andrology
October 2024
AbbVie, Inc., North Chicago, Illinois, USA.
Article Synopsis
- This study evaluated the effects of testosterone gel 1.62% on 24-hour ambulatory blood pressure (BP) in men with low testosterone levels, revealing inconsistent results from earlier studies on testosterone treatments.
- Conducted as a single-arm trial with nearly 250 participants over 16 weeks, the study aimed to see if the increase in serum testosterone would significantly affect systolic blood pressure (SBP).
- The findings indicated a slight rise in average SBP (1.9 mm Hg), but the increase wasn't definitively outside the non-inferiority margin, suggesting that while changes were observed, their clinical significance remains uncertain, particularly among men with hypertension or diabetes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!